Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth
Executive Summary
Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.
You may also be interested in...
Earnings Briefs: Biogen, Celgene, Actelion, Cubist
Biogen gains approval for its latest MS treatment in the EU; Celgene pushes ahead with Otezla, despite soft launch; Actelion looking outside PAH for business development; Cubist developing patient access program for Sivextro.
Two New Sides Of Cubist: Antibiotics Maker Buys Both Optimer And Trius
The Boston-area company will no longer rely as heavily on the antibiotic Cubicin, once it takes out its partner on a second marketed drug and, separately, a clinical-stage antibiotics company. The deals give Cubist territorial rights to Optimer’s Dificid for C. diff and Trius’s tedizolid for Gram-positive infections for $535 million and $707 million, respectively, plus CVRs.
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.